Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026
Same author

Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.

Immunobiology·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

The Journal of clinical investigation·2026

Related Experiment Video

Updated: Dec 2, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

4-1BB (CD137) in anticancer chimeras.

Ignacio Melero1,2,3,4, Pedro Berraondo1,2,3

  • 1Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

The Journal of Experimental Medicine
|November 4, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces a novel chimeric receptor combining Fas and 4-1BB to enhance T cell activation and persistence. This breakthrough significantly improves adoptive T cell therapy outcomes for cancer treatment.

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K

Related Experiment Videos

Last Updated: Dec 2, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Therapy

Background:

  • 4-1BB (CD137, TNFRSF9) is crucial for T cell activation and survival.
  • Enhancing T cell function is key for effective adoptive T cell therapy.

Purpose of the Study:

  • To develop an improved chimeric receptor for adoptive T cell therapy.
  • To leverage 4-1BB signaling for enhanced T cell-mediated immunity.

Main Methods:

  • Construction of a chimeric receptor with extracellular Fas and intracellular 4-1BB domains.
  • Evaluation of the chimeric receptor's impact on T cell activation and persistence.

Main Results:

  • The chimeric Fas-4-1BB receptor significantly boosts T cell activation.
  • Improved persistence of cytotoxic T lymphocytes was observed.

Conclusions:

  • Chimeric Fas-4-1BB receptor enhances adoptive T cell therapy.
  • This strategy offers a promising approach for improving cancer immunotherapy.